Advent, CVC Among Suitors for €3 Billion Viatris OTC Assets (1)

Advent International’s Zentiva generics business and Bain Capital-backed drugmaker Stada Arzneimittel AG are suitors considering bids for for Viatris Inc.’s European consumer-health assets, people familiar with the matter said.

The portfolio is also attracting potential interest from CVC Capital Partners, the owner of Cooper Consumer Health, as well as TPG Inc., which controls iNova Pharmaceuticals, the people said. The possible sale could fetch about €3 billion ($3.2 billion), according to the people, who asked not to be identified because the information is private.

Viatris has asked for preliminary offers for the business in February, the ...